|
Home | Medical-Newswire.Com:
|
(Medical-NewsWire.com, January 18, 2018 ) Global ovarian cancer treatment market estimated to be valued US$ XX Mn in 2017 and poised to grow at CAGR of XX% over 2017-2023. Market for ovarian cancer treatment is projected to reach US$ XX Mn by 2023.
Ovarian cancer is a type of cancer, which affects ovaries it causes rapid and abnormal increase of cell growth in ovaries. The exact cause of cancer is still unknown. An epithelial tumour, germ cell tumour and primary peritoneal carcinoma are types of ovarian cancer. Common symptoms include pressure in pelvis or lower back, changes in bowel movements, tiredness or low energy and more frequent urination. In most of the ovarian cancer cases, cancer will not be diagnosed until it has progressed to an advanced stage. Ovarian cancer is one of most common cause of cancer deaths in woman. Thereby need for development of the more effective drugs in treatment of ovarian cancer.
For more information http://www.reportsweb.com/global-ovarian-cancer-treatment-market-and-forecast-2017-2023
Increase in incidence of ovarian cancer worldwide is driving the ovarian cancer treatment market. According to WHO, an estimated 238,700 woman are diagnosed with ovarian cancer in 2012. The increase in older woman population, rising government funding and raising health care awareness able to grow ovarian cancer treatment market over the forecast period. According to ovarian cancer research fund alliance, the rate of prevalence of ovarian cancer is higher in woman between 55 to 66 years, many of the cancer foundations are funding to educate patients and healthcare professionals regarding symptoms and treatment options for ovarian cancer which may impact ovarian cancer market revenue growth positively over a forecast period. However, availability of generic drugs, lack of accurate diagnosis of ovarian cancer, and patient expiry of the key patented drugs like gemzar, taxol and paraplatin are expected to hamper the ovarian cancer treatment market.
Ovarian cancer treatment market segmented on the basis of type of cancer, drug class, and stage
Based on type of cancer, ovarian cancer treatment market is segmented into
Epithelial Ovarian Tumor
Ovarian Germ Cell Tumor
Ovarian Stomatal Tumor
Primary Peritoneal Carcinoma
Based on drug class, ovarian cancer treatment market is segmented into
Chemotherapeutic Agents
Targeted Therapy Drugs
Immune System Modulators
Hormones
Based on distribution channel, ovarian cancer treatment market is segmented into
Hospital Pharmacies
Retail Pharmacies
Others
Request Sample Copy http://www.reportsweb.com/inquiry&RW00011411999/sample
Companies operating in ovarian cancer market investing in developing new drug therapies and finding newer molecular targets to treat ovarian cancer. For instance, Vintafolide an investigational targeted cancer therapeutic currently under development by Endocyte and Merck & Co. and faltetuzumab a monoclonal antibody being investigated for the treatment of ovarian cancer this was developed by Morphotek, Inc. The introduction of new drug therapies like gene therapy, radiation therapy and targeted drug therapy are projected to improve ovarian cancer market revenue growth over forecast period. Global ovarian cancer market currently dominated by generic drugs and development of more effective drugs is challenging for market players. Some of the new drugs like avastin, lynparza and yondelis are approved in recent years to treat cancer and these drugs are slowly capturing market share.
Geographically ovarian cancer treatment market has been segmented into following regions viz. North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. North America dominates the ovarian cancer treatment market due to rising number of ageing population. According to American cancer society, in U.S. about 22,440 women will receive a new diagnosis of ovarian cancer and about 14,080 women will die from ovarian cancer in 2017. Europe is largest market as the incidence rates of ovarian cancer is increased in the region.
Some of the players in ovarian cancer treatment market include Eli Lilly and Company (U.S.), Johnson & Johnson Services, Inc. (U.S.), Novogen Limited (Australia) , Aeterna Zentaris Inc. (U.S)., GlaxoSmithKline plc (UK), Boehringer Ingelheim GmbH (Germany) and F. Hoffmann-La Roche AG (Switzerland) to name a few.
In December 2016 FDA approved rucaparib for the treatment of woman with advanced ovarian cancer who have received two or more prior chemotherapies and whose tumours have BRCA gene mutation
Report Outline:
The report provides granular level information about the market size, regional market share and forecast from 2017-2023
The report covers in-detail insights about the competitor's overview, key findings and their key strategies
The report outlines drivers, restraints, challenges, and trends that are currently faced by the industry
The report tracks recent innovations, key developments and startup's details that are working in the industry
The report provides plethora of information about market entry strategies, regulatory framework and reimbursement scenario
Make an enquiry: http://www.reportsweb.com/inquiry&RW00011411999/buying
ReportsWeb.com
Rajat Sahni
+1-646-491-9876
sales@reportsweb.com
Source: EmailWire.Com 
Source: EmailWire.com
|
|
|
|
